Rocket secures up to USD 150 million: what it means for Rocket Pharmaceuticals stock

Published on 10/07/2026 at 04:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rocket received USD 35.00 million at closing on September 30, 2026. Rocket Pharmaceuticals stock stood at EUR 2.23 on October 5, 2026.

RCKT, US77313F1066, Illustration mit AI erstellt.

Rocket Pharmaceuticals, Inc. (ISIN US77313F1066) had a EUR 2.23 prior close at Lang & Schwarz on October 5, 2026. According to Business Wire on October 6, 2026, the biotechnology company announced a credit facility of up to USD 150.00 million with Hercules Capital. The financing is designed to support Rocket's pivotal Phase 2 study of RP-A501 for Danon disease and its cardiovascular pipeline.

USD 150 million facility

The agreement provides USD 35.00 million at closing, with another USD 35.00 million available at Rocket's option during specified periods. A further USD 30.00 million depends on a Danon clinical milestone, while USD 50.00 million requires approval from Hercules Capital's investment committee, according to Business Wire.

The initial draw represents 23.33 percent of the facility's maximum size. The loan has an initial 30-month interest-only period and a 48-month maturity, with extensions tied to specified milestones. Rocket also issued warrants to purchase common stock, adding potential dilution alongside the secured debt.

Cash runway reaches 2028

As of June 30, 2026, Rocket held USD 283.70 million in cash, cash equivalents and investments, according to Business Wire. Management said those resources, together with the initial USD 35.00 million draw, are expected to fund planned operations into the third quarter of 2028.

That runway estimate depends on the company's operating plan and the conditions attached to future borrowing. Additional draws could extend funding into 2029, while the financing terms include minimum-cash covenants and repayment obligations that link financial flexibility to clinical progress.

Market value remains below USD 300 million

RCKT's market capitalization was USD 270.80 million on October 6, 2026, while its 52-week range was USD 2.46 to USD 5.45. Those figures place the company's equity value near the lower end of its annual trading range, even as the new facility adds capital for the Danon program.

Prior close stands at EUR 2.23

Rocket Pharmaceuticals had a prior close of EUR 2.23 at Lang & Schwarz on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Rocket Pharmaceuticals stock.